Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184076 | 1.00 | HRH3 (0.46) | HRH3KCNH2HPGDEGFRRAB9A | |
| SCHEMBL2184275 | 0.93 | RAB9A (0.52) | EGFRRAB9AKDR | |
| SCHEMBL2184285 | 0.93 | RAB9A (0.52) | EGFRRAB9AKDR | |
| SCHEMBL12415213 | 0.93 | EPHX2 (0.51) | HRH3KCNH2EGFREPHX2MAPT | |
| SCHEMBL12506969 | 0.88 | HRH3 (0.47) | HRH3KCNH2HPGDEGFRRAB9A | |
| SCHEMBL2184331 | 0.88 | MEN1 (0.54) | HRH3KCNH2HPGDEGFREPHX2 | |
| SCHEMBL14077055 | 0.84 | MEN1 (0.43) | MAPT | |
| SCHEMBL2184082 | 0.83 | IDO1 (0.47) | HRH3KCNH2 | |
| SCHEMBL12506965 | 0.81 | EPHX2 (0.52) | HRH3KCNH2EGFREPHX2MAPT | |
| SCHEMBL12507281 | 0.81 | RAB9A (0.52) | EGFRRAB9AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064194-B1 | N-HYDROXYAMIDINOHETEROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE HOLDINGS CORP (US) | 2018-11-07 | — | — | EP | claimed |
| US-8507541-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-08-13 | — | — | US | claimed |
| US-20110165188-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation a Delaware corporation | 2011-07-07 | — | — | US | claimed |
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-09-04 | — | — | US | claimed |
| EP-2064194-B1 | N-HYDROXYAMIDINOHETEROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE HOLDINGS CORP (US) | 2018-11-07 | — | — | EP | disclosed |
| US-8507541-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110165188-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation a Delaware corporation | 2011-07-07 | — | — | US | disclosed |
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214546-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | HRH3 44/4885KCNH2 2597/4885HPGD 80/4885 |
| US-20110165188-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | HRH3 44/4885KCNH2 2597/4885HPGD 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.